Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Public ClinicalTrials.gov record NCT02798211. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
Study identification
- NCT ID
- NCT02798211
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 258 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2016 (Actual)
- Primary completion
- Dec 5, 2018 (Actual)
- Completion
- Dec 5, 2018 (Actual)
- Last update posted
- Oct 7, 2021
2016 – 2018
United States locations
- U.S. sites
- 57
- U.S. states
- 21
- U.S. cities
- 54
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35205 | — |
| Novartis Investigative Site | Little Rock | Arkansas | 72205 | — |
| Novartis Investigative Site | El Cajon | California | 92020 | — |
| Novartis Investigative Site | Fountain Valley | California | 92708 | — |
| Novartis Investigative Site | La Jolla | California | 92093 | — |
| Novartis Investigative Site | La Mesa | California | 91942 | — |
| Novartis Investigative Site | Upland | California | 91786 | — |
| Novartis Investigative Site | Aventura | Florida | 33180 | — |
| Novartis Investigative Site | Clearwater | Florida | 33765 | — |
| Novartis Investigative Site | DeBary | Florida | 32713 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32207 | — |
| Novartis Investigative Site | North Naples | Florida | 34102 | — |
| Novartis Investigative Site | Palm Harbor | Florida | 34684 | — |
| Novartis Investigative Site | Pensacola | Florida | 32514 | — |
| Novartis Investigative Site | Plantation | Florida | 33324 | — |
| Novartis Investigative Site | Sarasota | Florida | 34239 | — |
| Novartis Investigative Site | Tampa | Florida | 33609 | — |
| Novartis Investigative Site | Tampa | Florida | 33613 | — |
| Novartis Investigative Site | Duluth | Georgia | 30096 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21224 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Worcester | Massachusetts | 01655 | — |
| Novartis Investigative Site | Battle Creek | Michigan | 49015 | — |
| Novartis Investigative Site | Kalamazoo | Michigan | 49008 | — |
| Novartis Investigative Site | Eagan | Minnesota | 55121 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68516 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89106 | — |
| Novartis Investigative Site | Ridgewood | New Jersey | 07450 | — |
| Novartis Investigative Site | Summit | New Jersey | 07901 | — |
| Novartis Investigative Site | Albany | New York | 12206 | — |
| Novartis Investigative Site | Brooklyn | New York | 11201 | — |
| Novartis Investigative Site | Lake Success | New York | 11402 | — |
| Novartis Investigative Site | Orchard Park | New York | 14127 | — |
| Novartis Investigative Site | Potsdam | New York | 13676 | — |
| Novartis Investigative Site | Saranac Lake | New York | 12983 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28226 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27408 | — |
| Novartis Investigative Site | New Bern | North Carolina | 28562 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Perrysburg | Ohio | 43551 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29460 | — |
| Novartis Investigative Site | Greenville | South Carolina | 29601 | — |
| Novartis Investigative Site | Orangeburg | South Carolina | 29118-2475 | — |
| Novartis Investigative Site | Jackson | Tennessee | 38305 | — |
| Novartis Investigative Site | Arlington | Texas | 76014 | — |
| Novartis Investigative Site | Arlington | Texas | 77373 | — |
| Novartis Investigative Site | Austin | Texas | 78731 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Houston | Texas | 77074 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02798211, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02798211 live on ClinicalTrials.gov.